The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
News|Articles|December 13, 2004
New Product Newswire
Omacor, (omega-3 acid ethyl esters) will be marketed in the United States by Reliant Pharmaceuticals, Liberty Corner, N.J., (908) 580-1200.
Advertisement
Advertisement
Related to this article
The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
How the Main Street Pharmacy Access Act Advances Pharmacist Provider Status
3
Generic Drug Costs Burdening Patients as Much as Brand Name Options
4
COVID-19 Vaccine Hesitancy in 2026: How Attitudes Have Shifted
5